<html>
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<style type="text/css">
.txt { white-space:nowrap; }
#f0 { font-family:sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff0; src: url("0.ttf"); }
#f1 { font-family:ff0,sans-serif; font-weight:bold; font-style:normal; }
@font-face { font-family: ff1; src: url("1.ttf"); }
#f2 { font-family:ff1,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff2; src: url("2.ttf"); }
#f3 { font-family:ff2,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff3; src: url("3.ttf"); }
#f4 { font-family:ff3,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff4; src: url("4.ttf"); }
#f5 { font-family:ff4,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff5; src: url("5.ttf"); }
#f6 { font-family:ff5,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff6; src: url("6.ttf"); }
#f7 { font-family:ff6,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff7; src: url("7.ttf"); }
#f8 { font-family:ff7,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff8; src: url("8.ttf"); }
#f9 { font-family:ff8,monospace; font-weight:bold; font-style:normal; }
@font-face { font-family: ff9; src: url("9.ttf"); }
#f10 { font-family:ff9,serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff10; src: url("10.ttf"); }
#f11 { font-family:ff10,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff11; src: url("11.ttf"); }
#f12 { font-family:ff11,sans-serif; font-weight:normal; font-style:normal; }
</style>
</head>
<body>
<img id="background" style="position:absolute; left:0px; top:0px;" width="595" height="842" src="page1.png">
<div class="txt" style="position:absolute; left:478px; top:72px;"><span id="f2" style="font-size:12px;vertical-align:baseline;color:rgba(0,0,0,1);">기업 </span><span id="f1" style="font-size:12px;vertical-align:baseline;color:rgba(0,0,0,1);">Note</span></div>
<div class="txt" style="position:absolute; left:497px; top:92px;"><span id="f1" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">2017.8.22</span></div>
<div class="txt" style="position:absolute; left:190px; top:161px;"><span id="f11" style="font-size:20px;vertical-align:baseline;color:rgba(0,160,198,1);">삼성바이오로직스(207940)</span></div>
<div class="txt" style="position:absolute; left:28px; top:192px;"><span id="f2" style="font-size:18px;vertical-align:baseline;color:rgba(0,0,0,1);">매수(유지)</span></div>
<div class="txt" style="position:absolute; left:190px; top:193px;"><span id="f12" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">장차 크게 될 회사</span></div>
<div class="txt" style="position:absolute; left:28px; top:223px;"><span id="f2" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">목표주가: 350,000원(유지)</span></div>
<div class="txt" style="position:absolute; left:28px; top:252px;"><span id="f5" style="font-size:8px;vertical-align:baseline;color:rgba(0,0,0,1);">Stock Data</span></div>
<div class="txt" style="position:absolute; left:28px; top:267px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">KOSPI(8/21)</span></div>
<div class="txt" style="position:absolute; left:157px; top:267px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">2,355</span></div>
<div class="txt" style="position:absolute; left:28px; top:278px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">주가(8/21)</span></div>
<div class="txt" style="position:absolute; left:149px; top:278px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">274,500</span></div>
<div class="txt" style="position:absolute; left:28px; top:290px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">시가총액(십억원)</span></div>
<div class="txt" style="position:absolute; left:153px; top:290px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">18,162</span></div>
<div class="txt" style="position:absolute; left:28px; top:301px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">발행주식수(백만)</span></div>
<div class="txt" style="position:absolute; left:166px; top:301px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">66</span></div>
<div class="txt" style="position:absolute; left:28px; top:313px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">52주 최고/최저가(원)</span></div>
<div class="txt" style="position:absolute; left:123px; top:313px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">297,000/142,000</span></div>
<div class="txt" style="position:absolute; left:28px; top:324px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">일평균거래대금(6개월, 백만원)</span></div>
<div class="txt" style="position:absolute; left:153px; top:324px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">64,087</span></div>
<div class="txt" style="position:absolute; left:28px; top:335px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">유동주식비율/외국인지분율(%)</span></div>
<div class="txt" style="position:absolute; left:149px; top:335px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">21.8/9.6</span></div>
<div class="txt" style="position:absolute; left:28px; top:347px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">주요주주(%) 삼성물산 외 3 인</span></div>
<div class="txt" style="position:absolute; left:160px; top:347px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">75.0</span></div>
<div class="txt" style="position:absolute; left:28px; top:377px;"><span id="f5" style="font-size:8px;vertical-align:baseline;color:rgba(0,0,0,1);">주가상승률</span></div>
<div class="txt" style="position:absolute; left:28px; top:399px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">절대주가(%)</span></div>
<div class="txt" style="position:absolute; left:28px; top:409px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">상대주가(%p)</span></div>
<div class="txt" style="position:absolute; left:92px; top:389px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">1개월</span></div>
<div class="txt" style="position:absolute; left:99px; top:399px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">1.7</span></div>
<div class="txt" style="position:absolute; left:99px; top:409px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">5.5</span></div>
<div class="txt" style="position:absolute; left:125px; top:389px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">6개월</span></div>
<div class="txt" style="position:absolute; left:128px; top:399px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">65.9</span></div>
<div class="txt" style="position:absolute; left:128px; top:409px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">53.9</span></div>
<div class="txt" style="position:absolute; left:154px; top:389px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">12개월</span></div>
<div class="txt" style="position:absolute; left:164px; top:399px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">0.0</span></div>
<div class="txt" style="position:absolute; left:164px; top:409px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">0.0</span></div>
<div class="txt" style="position:absolute; left:28px; top:427px;"><span id="f5" style="font-size:8px;vertical-align:baseline;color:rgba(0,0,0,1);">12MF PBR 추이</span></div>
<div class="txt" style="position:absolute; left:29px; top:444px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">6.0</span></div>
<div class="txt" style="position:absolute; left:46px; top:441px;"><span id="f8" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">(배)</span></div>
<div class="txt" style="position:absolute; left:29px; top:458px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">5.0</span></div>
<div class="txt" style="position:absolute; left:29px; top:473px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">4.0</span></div>
<div class="txt" style="position:absolute; left:75px; top:442px;"><span id="f8" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">12MF PBR (좌)</span></div>
<div class="txt" style="position:absolute; left:139px; top:441px;"><span id="f8" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">(천원)</span></div>
<div class="txt" style="position:absolute; left:166px; top:444px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">400</span></div>
<div class="txt" style="position:absolute; left:75px; top:451px;"><span id="f8" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">삼성바이오로직스 주가 (우)</span></div>
<div class="txt" style="position:absolute; left:166px; top:455px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">350</span></div>
<div class="txt" style="position:absolute; left:166px; top:466px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">300</span></div>
<div class="txt" style="position:absolute; left:166px; top:477px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">250</span></div>
<div class="txt" style="position:absolute; left:29px; top:488px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">3.0</span></div>
<div class="txt" style="position:absolute; left:166px; top:488px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">200</span></div>
<div class="txt" style="position:absolute; left:166px; top:499px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">150</span></div>
<div class="txt" style="position:absolute; left:29px; top:503px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">2.0</span></div>
<div class="txt" style="position:absolute; left:166px; top:510px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">100</span></div>
<div class="txt" style="position:absolute; left:29px; top:517px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">1.0</span></div>
<div class="txt" style="position:absolute; left:166px; top:521px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">50</span></div>
<div class="txt" style="position:absolute; left:29px; top:532px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">0.0</span></div>
<div class="txt" style="position:absolute; left:166px; top:532px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">0</span></div>
<div class="txt" style="position:absolute; left:35px; top:537px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">Sep-14</span></div>
<div class="txt" style="position:absolute; left:75px; top:537px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">Sep-15</span></div>
<div class="txt" style="position:absolute; left:116px; top:537px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">Sep-16</span></div>
<div class="txt" style="position:absolute; left:28px; top:546px;"><span id="f5" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">자료: WISEfn 컨센서스</span></div>
<div class="txt" style="position:absolute; left:189px; top:227px;"><span id="f6" style="font-size:10px;vertical-align:baseline;color:rgba(0,160,198,1);">신약개발이라는 장기적 청사진을 제시하다</span></div>
<div class="txt" style="position:absolute; left:189px; top:242px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">삼성바이오로직스의 자회사 바이오에피스는 어제 언론보도를 통해 일본의 다케다제약과</span></div>
<div class="txt" style="position:absolute; left:189px; top:255px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">바이오신약 개발을 공동진행하는 전략적 협력계약을 체결했다고 밝혔다. 바이오시밀러를</span></div>
<div class="txt" style="position:absolute; left:189px; top:268px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">넘어 신약개발이라는 장기적 청사진을 제시함에 따라 삼성바이오로직스의 향후 사업의 방</span></div>
<div class="txt" style="position:absolute; left:189px; top:281px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">향성은 CMO 세계 1위 등극/글로벌 신약개발업체로의 변모로 대변할 수 있을 것이다.</span></div>
<div class="txt" style="position:absolute; left:189px; top:307px;"><span id="f6" style="font-size:10px;vertical-align:baseline;color:rgba(0,160,198,1);">급성췌장암 치료제 공동개발 착수</span></div>
<div class="txt" style="position:absolute; left:189px; top:322px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">다케다제약은 1781년 일본에서 창업한 회사로, 지난해 161억 달러의 매출을 기록한 아시</span></div>
<div class="txt" style="position:absolute; left:189px; top:335px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">아 최대 다국적 제약사다. 두 회사간의 계약은 신물질 탐색, 임상허가, 상업화에 이르는</span></div>
<div class="txt" style="position:absolute; left:189px; top:348px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">전 과정을 협력하여 비용 등의 리스크를 줄이고 개발성공 가능성을 높이려는 전략이다.</span></div>
<div class="txt" style="position:absolute; left:189px; top:361px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">양사의 첫 프로젝트는 급성 췌장염 치료제의 공동개발이다. 급성 췌장염 치료제는 아직</span></div>
<div class="txt" style="position:absolute; left:189px; top:374px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">개발되지 않은 제품이며 다케다약품이 소화기 내과 분야 치료제에 강점을 갖고 있어 적절</span></div>
<div class="txt" style="position:absolute; left:189px; top:387px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">한 초기전략이 수립된 것으로 보여진다.</span></div>
<div class="txt" style="position:absolute; left:189px; top:414px;"><span id="f6" style="font-size:10px;vertical-align:baseline;color:rgba(0,160,198,1);">실적은 돌아서고, 신제품은 잇달아 출시되고</span></div>
<div class="txt" style="position:absolute; left:189px; top:429px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">일시적인 가동률 하락으로 영업적자를 시현했던 2분기를 뒤로하고 삼성바이오로직스는 3</span></div>
<div class="txt" style="position:absolute; left:189px; top:442px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">분기부터 흑자기조를 이어갈 전망이다. 한편 올해 7월 말 미국에서 Remicade 바이오시밀</span></div>
<div class="txt" style="position:absolute; left:189px; top:455px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">러 렌플렉시스를 출시한 바이오에피스는 유럽에서 올해 내로 Herceptin(유방암 치료제)의</span></div>
<div class="txt" style="position:absolute; left:189px; top:468px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">첫 바이오시밀러 출시에 대한 승인이 기대된다. 내년 상반기에는 Humira의 바이오시밀러</span></div>
<div class="txt" style="position:absolute; left:189px; top:481px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">임랄디, Lantus의 바이오시밀러 루수두나 등의 유럽 출시가 잇달아 예정되어 있다. 삼성</span></div>
<div class="txt" style="position:absolute; left:189px; top:494px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">바이오로직스와 바이오에피스의 향후 실적개선에 대한 기대감은 하반기로 갈수록 고조될</span></div>
<div class="txt" style="position:absolute; left:189px; top:507px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">전망이다.</span></div>
<div class="txt" style="position:absolute; left:189px; top:535px;"><span id="f6" style="font-size:10px;vertical-align:baseline;color:rgba(0,160,198,1);">CMO 세계 1위/글로벌 신약개발업체에 대해 긴 호흡에서 매수권고</span></div>
<div class="txt" style="position:absolute; left:189px; top:549px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">삼성바이오로직스에 대해 매수 투자의견과 목표주가 35만원을 유지한다. 목표주가는</span></div>
<div class="txt" style="position:absolute; left:189px; top:562px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">2017년~2023년의 free cash flow를 합산해 현재 가치로 할인한 후 자회사 지분가치(바</span></div>
<div class="txt" style="position:absolute; left:189px; top:575px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">이오에피스 2.56조원[5.12조원의 50.1%], Archizen Biotech 340억원[680억원의 50%])와</span></div>
<div class="txt" style="position:absolute; left:189px; top:588px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">2017년 순현금과 콜옵션 행사금 5,982억원을 더해 산출했다. 3분기부터 영업흑자 기조를</span></div>
<div class="txt" style="position:absolute; left:189px; top:601px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">이어가는 한편 신약개발이라는 장기적인 청사진을 제시하는 삼성바이오로직스에 대해 긴</span></div>
<div class="txt" style="position:absolute; left:189px; top:614px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">호흡에서 매수를 권고한다.</span></div>
<div class="txt" style="position:absolute; left:29px; top:731px;"><span id="f5" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">진홍국 </span><span id="f5" style="font-size:8px;vertical-align:baseline;color:rgba(0,0,0,1);">3276-6196</span></div>
<div class="txt" style="position:absolute; left:29px; top:743px;"><span id="f3" style="font-size:8px;vertical-align:baseline;color:rgba(0,0,0,1);">hg.jin@truefriend.com</span></div>
<div class="txt" style="position:absolute; left:29px; top:761px;"><span id="f5" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">정은영 </span><span id="f5" style="font-size:8px;vertical-align:baseline;color:rgba(0,0,0,1);">3276-6239</span></div>
<div class="txt" style="position:absolute; left:28px; top:771px;"><span id="f3" style="font-size:8px;vertical-align:baseline;color:rgba(0,0,0,1);">eunice.jung@truefriend.com</span></div>
<div class="txt" style="position:absolute; left:228px; top:694px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">매출액 영업이익 순이익</span></div>
<div class="txt" style="position:absolute; left:336px; top:694px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">EPS 증감률 EBITDA PER </span><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">EV/EBITDA </span><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">PBR ROE DY</span></div>
<div class="txt" style="position:absolute; left:223px; top:706px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">(십억원) (십억원) (십억원)</span></div>
<div class="txt" style="position:absolute; left:338px; top:706px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">(원)</span></div>
<div class="txt" style="position:absolute; left:367px; top:706px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">(%) (십억원)</span></div>
<div class="txt" style="position:absolute; left:428px; top:706px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">(x)</span></div>
<div class="txt" style="position:absolute; left:457px; top:706px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">(x) (x) (%) (%)</span></div>
<div class="txt" style="position:absolute; left:189px; top:717px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">2015A</span></div>
<div class="txt" style="position:absolute; left:240px; top:717px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">91</span></div>
<div class="txt" style="position:absolute; left:265px; top:717px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">(204) 1,905 19,414</span></div>
<div class="txt" style="position:absolute; left:368px; top:717px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">NM (162) NM</span></div>
<div class="txt" style="position:absolute; left:455px; top:717px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">NM NM 68.7</span></div>
<div class="txt" style="position:absolute; left:534px; top:717px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">-</span></div>
<div class="txt" style="position:absolute; left:189px; top:728px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">2016A</span></div>
<div class="txt" style="position:absolute; left:236px; top:728px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">295</span></div>
<div class="txt" style="position:absolute; left:269px; top:728px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">(30)</span></div>
<div class="txt" style="position:absolute; left:300px; top:728px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">(177) (1,558)</span></div>
<div class="txt" style="position:absolute; left:368px; top:728px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">NM</span></div>
<div class="txt" style="position:absolute; left:402px; top:728px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">30 NM 320.6 4.9 (5.2)</span></div>
<div class="txt" style="position:absolute; left:534px; top:728px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">-</span></div>
<div class="txt" style="position:absolute; left:189px; top:740px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">2017F</span></div>
<div class="txt" style="position:absolute; left:236px; top:740px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">415</span></div>
<div class="txt" style="position:absolute; left:277px; top:740px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">7</span></div>
<div class="txt" style="position:absolute; left:300px; top:740px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">(129) (1,954)</span></div>
<div class="txt" style="position:absolute; left:368px; top:740px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">NM</span></div>
<div class="txt" style="position:absolute; left:402px; top:740px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">69 NM 262.5 5.1 (3.4)</span></div>
<div class="txt" style="position:absolute; left:534px; top:740px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">-</span></div>
<div class="txt" style="position:absolute; left:189px; top:751px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">2018F</span></div>
<div class="txt" style="position:absolute; left:236px; top:751px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">573</span></div>
<div class="txt" style="position:absolute; left:270px; top:751px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">110</span></div>
<div class="txt" style="position:absolute; left:304px; top:751px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">497 7,516</span></div>
<div class="txt" style="position:absolute; left:368px; top:751px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">NM</span></div>
<div class="txt" style="position:absolute; left:399px; top:751px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">185 36.5 96.1 4.5 13.1</span></div>
<div class="txt" style="position:absolute; left:534px; top:751px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">-</span></div>
<div class="txt" style="position:absolute; left:189px; top:762px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">2019F</span></div>
<div class="txt" style="position:absolute; left:236px; top:762px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">944</span></div>
<div class="txt" style="position:absolute; left:270px; top:762px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">330</span></div>
<div class="txt" style="position:absolute; left:304px; top:762px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">266 4,022 (46.5)</span></div>
<div class="txt" style="position:absolute; left:399px; top:762px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">436 68.2 40.2 4.5 6.6</span></div>
<div class="txt" style="position:absolute; left:534px; top:762px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">-</span></div>
</body>
</html>
